Report Description Table of Contents How Are Rising HPB Surgical Volumes, Minimally Invasive Procedures, and Advanced Surgical Technologies Shaping the HPB Surgical Devices Market? – (Updated On: 21st-Nov-2026) According to Strategic Market Research, the Global HPB Surgical Devices Market was estimated at USD 5.83 billion in 2025 and is projected to reach USD 8.98 billion by 2032, expanding at a CAGR of 6.4% during 2026–2032. Increasing adoption of minimally invasive hepatopancreatobiliary surgery, growing liver transplantation activity, and advances in robotic surgical systems, tissue-dissection instruments, and intraoperative visualization are influencing device demand. The market serves liver resections, pancreatic operations, cholecystectomies, biliary reconstruction, and liver transplantation. Growth opportunities differ across procedures, with routine gallbladder operations generating high instrument utilization and complex HPB surgery supporting demand for specialized devices. These market values are provisional analyst estimates rather than independently verified industry revenues. High-volume gallbladder surgery remains a major contributor to HPB surgical device utilization. The Japan Surgical Society's 2024 National Clinical Database Annual Report recorded 120,625 laparoscopic cholecystectomies, making the procedure the largest category within its hepatobiliary and pancreatic surgery classification. This surgical volume demonstrates the established demand for laparoscopic access instruments, energy devices, surgical clips, and visualization equipment. For manufacturers, routine cholecystectomy represents a recurring consumables opportunity, although standardized hospital purchasing and competition among instrument suppliers can restrict revenue growth per procedure. Complex pancreatic surgery creates a concentrated market for specialized surgical instruments and advanced resection technologies. The German Cancer Society's 2025 Pancreatic Center Report documented 7,184 pancreatic resections during the 2023 reporting year across participating certified centers. These operations support demand for surgical staplers, vessel-sealing devices, tissue-dissection equipment, and reconstruction instruments. Unlike routine laparoscopic procedures, pancreatic surgery is concentrated in specialist hospitals, making surgical center relationships, procedural expertise, and reliable device performance important determinants of supplier adoption. The reported count covers participating certified centers rather than all pancreatic operations performed in Germany. Liver transplantation activity is supporting demand for advanced hepatic dissection and bleeding-control devices. The U.S. Department of Health and Human Services recorded 12,344 liver transplants in 2025, reflecting substantial utilization of specialized HPB surgical services. These operations require coordinated use of tissue-dissection systems, vascular instruments, hemostatic products, and surgical closure devices. Commercial opportunities are concentrated in transplant hospitals, where consistent surgical throughput and established purchasing relationships determine recurring instrument demand. Manufacturers specializing in liver surgery equipment, including Integra LifeSciences, are positioned to serve this clinically demanding segment. Robotic-assisted liver surgery is gaining adoption within specialized minimally invasive HPB programs. A 2026 study published in Langenbeck's Archives of Surgery, analyzing 8,928 minimally invasive liver resections in the I Go MILS registry, found that the robotic share increased from 10.4% to 42.2% between 2015 and 2025. Although these findings reflect participating centers rather than global practice, they indicate a substantial shift in surgical approach. This transition creates opportunities for robotic instruments, compatible energy devices, and integrated surgical systems, while requiring manufacturers to demonstrate sufficient utilization and clinical value to justify hospital investment. The higher cost of robotic surgery could influence equipment selection and slow adoption in routine HPB procedures. A 2025 study published in Surgery, examining cholecystectomies across a U.S. healthcare system, reported average disposable instrument costs of USD 1,447 for robotic procedures compared with USD 669 for laparoscopic procedures. This cost differential creates purchasing pressure for hospitals performing large volumes of routine gallbladder operations. Robotic platforms may achieve stronger commercial acceptance in selected complex cases where their clinical benefits justify additional expenditure, while conventional laparoscopic instruments retain a cost advantage in routine surgical care. Market Outlook: The Global HPB Surgical Devices Market is projected to generate an additional USD 3.15 billion in annual market revenue between 2025 and 2032, reaching USD 8.98 billion. Market expansion will depend on the number of liver resections, pancreatic surgeries, cholecystectomies, and liver transplantations performed annually, increasing adoption of laparoscopic and robotic-assisted procedures, utilization of advanced surgical instruments, and average device expenditure per operation. Growth will also be influenced by hospital investment in surgical imaging and robotic platforms, while procedural costs, reimbursement policies, and surgical capacity will determine the pace of adoption. Which Subsegments Lead the HPB Surgical Devices Market, and Which Are Advancing Fastest? Leading Subsegments Across Market Categories Energy and Vessel Sealing Devices – Leading Product Type Energy and vessel sealing devices accounted for the largest estimated 19.0% share of the Global HPB Surgical Devices Market in 2025, valued at USD 1.107 billion, and are projected to reach USD 1.607 billion by 2032, registering a CAGR of 5.5% during 2026–2032. The Japan Surgical Society recorded 120,625 laparoscopic cholecystectomies in 2024, demonstrating a substantial procedural base for energy instruments used in gallbladder surgery. Medtronic's LigaSure and competing energy devices serve both routine laparoscopic and complex HPB operations. Hospital-wide procurement contracts can generate recurring instrument demand, although standardized purchasing and competition among vessel-sealing products constrain pricing. Laparoscopic Surgery – Leading Surgical Approach Laparoscopic surgery accounted for the largest estimated 64.0% share of the Global HPB Surgical Devices Market in 2025, valued at USD 3.733 billion, and is projected to reach USD 5.429 billion by 2032, registering a CAGR of 5.5% during 2026–2032. OECD data recorded 87,986 laparoscopic cholecystectomies in the United Kingdom in 2024, providing a measurable base of procedures requiring laparoscopic equipment. Routine gallbladder operations generate recurring demand for trocars, surgical clips, energy devices and imaging accessories. Conventional laparoscopic systems remain commercially competitive in high-throughput surgical departments, particularly where hospitals prioritize lower disposable-device expenditure over robotic capabilities. Gallbladder Surgery – Leading Surgical Procedure/Application Gallbladder surgery accounted for the largest estimated 51.4% share of the Global HPB Surgical Devices Market in 2025, valued at USD 3.000 billion, and is projected to reach USD 4.120 billion by 2032, registering a CAGR of 4.6% during 2026–2032. Germany recorded 206,775 inpatient cholecystectomies in 2024, demonstrating the substantial operating volume associated with gallbladder removal. Device manufacturers serving this application compete through surgical access systems, vessel-sealing instruments, clips and visualization equipment. Recurring disposable consumption supports purchasing volumes, while hospital procurement standardization limits average revenue growth per procedure. Gallstones and Cholecystitis – Leading Indication Gallstones and cholecystitis accounted for the largest estimated 48.0% share of the Global HPB Surgical Devices Market in 2025, valued at USD 2.800 billion, and are projected to reach USD 3.950 billion by 2032, registering a CAGR of 5.0% during 2026–2032. A U.S. study published in 2024 identified approximately 605,000 annual ambulatory laparoscopic cholecystectomies using historical national utilization data, indicating substantial outpatient surgical activity associated with gallbladder disease. Manufacturers supplying laparoscopic instruments, surgical clips and energy devices benefit from recurring procedural purchasing, while competition is concentrated around instrument costs, availability and hospital supply agreements. The historical estimate should not be interpreted as a 2025 procedure count. Hospitals – Leading End User Hospitals accounted for the largest estimated 89.1% share of the Global HPB Surgical Devices Market in 2025, valued at USD 5.200 billion, and are projected to reach USD 7.810 billion by 2032, registering a CAGR of 6.0% during 2026–2032. The U.S. Department of Health and Human Services reported 12,344 liver transplants in 2025, demonstrating substantial demand for specialized instruments within transplant-capable hospitals. Advanced hepatic and pancreatic surgery concentrates equipment purchasing in tertiary referral centers, cancer hospitals and transplant programs. Manufacturers can secure recurring device utilization through specialist surgical departments, although purchasing decisions remain subject to hospital budgets and clinical evaluation. Asia-Pacific – Leading Geography Asia-Pacific accounted for the largest estimated 38.7% share of the Global HPB Surgical Devices Market in 2025, valued at USD 2.260 billion, and is projected to reach USD 3.735 billion by 2032, registering a CAGR of 7.4% during 2026–2032. The Japan Surgical Society recorded 8,456 pancreaticoduodenectomies involving lymphadenectomy and nerve plexus dissection in 2024, demonstrating established complex pancreatic surgical activity in the region. China, Japan and India represent important surgical equipment markets, although differences in hospital purchasing power, device pricing and access to specialized HPB care influence commercial opportunities. The region's estimated revenue leadership remains provisional because comprehensive national procedure data are unavailable for several major countries. Fastest-Advancing Subsegments Across Market Categories Robotic-Assisted Surgical Systems and Instruments – Fastest-Advancing Product Type Robotic-assisted surgical systems and instruments accounted for an estimated 17.9% share of the Global HPB Surgical Devices Market in 2025, valued at USD 1.042 billion, and are projected to reach USD 1.951 billion by 2032, registering the fastest product-segment CAGR of 9.4% during 2026–2032. Intuitive reported a global installed base of 12,094 da Vinci surgical systems as of September 30, 2026, providing an established multispecialty equipment network for eligible HPB operations. Competition from Medtronic's Hugo platform introduces additional hospital purchasing options. Manufacturers must convert installed platforms into completed HPB procedures and recurring instrument utilization to translate broader robotic adoption into device revenue. Robotic-Assisted Surgery – Fastest-Advancing Surgical Approach Robotic-assisted surgery accounted for an estimated 20.4% share of the Global HPB Surgical Devices Market in 2025, valued at USD 1.190 billion, and is projected to reach USD 2.393 billion by 2032, registering the fastest surgical-approach CAGR of 10.5% during 2026–2032. A 2026 I Go MILS registry analysis involving 8,928 minimally invasive liver resections found that robotic utilization increased from 10.4% to 42.2% between 2015 and 2025. This adoption within participating surgical centers creates demand for robotic instruments and compatible operating-room equipment. Higher equipment costs, surgeon training requirements and the availability of conventional laparoscopic alternatives remain important constraints on broader commercial penetration. Other HPB Surgical Procedures – Fastest-Growing Modeled Application Category Other HPB surgical procedures accounted for an estimated 4.3% share of the Global HPB Surgical Devices Market in 2025, valued at USD 0.253 billion, and are projected to reach USD 0.529 billion by 2032, registering a modeled CAGR of 11.1% during 2026–2032. Japan's National Clinical Database recorded 698 choledochoenterostomy procedures in 2024, illustrating the presence of specialized HPB operations beyond the largest surgical categories. Such procedures can involve specialized reconstruction and dissection instruments, but the residual segment includes heterogeneous operations with different purchasing requirements. Its projected growth cannot be independently validated without a more detailed procedure-level allocation; among defined applications, biliary tract surgery has the highest modeled growth rate. Other HPB Conditions – Fastest-Growing Modeled Indication Category Other HPB conditions accounted for an estimated 9.6% share of the Global HPB Surgical Devices Market in 2025, valued at USD 0.558 billion, and are projected to reach USD 0.969 billion by 2032, registering a modeled CAGR of 8.2% during 2026–2032. The U.S. National Cancer Institute projected 67,530 new pancreatic cancer cases in 2026, illustrating the scale of one clinically significant HPB disease population, although pancreatic cancer is classified separately from this residual indication. The category's mixed diagnoses prevent a direct link between the cited disease burden and its revenue forecast. Pancreatic cancer is the fastest-growing separately defined indication, with a modeled CAGR of 7.8%, while the residual category requires additional surgical procedure data before its growth ranking can be independently substantiated. Ambulatory Surgical Centers – Fastest-Advancing End User Ambulatory Surgical Centers accounted for an estimated 9.1% share of the Global HPB Surgical Devices Market in 2025, valued at USD 0.530 billion, and are projected to reach USD 0.990 billion by 2032, registering the fastest end-user CAGR of 9.3% during 2026–2032. A 2025 U.S. study reported average disposable instrument costs of USD 669 for laparoscopic cholecystectomy, demonstrating the importance of procedure-level purchasing economics in high-volume surgical settings. Ambulatory facilities offer opportunities for laparoscopic access instruments, surgical clips and other consumables used in eligible outpatient operations. Reimbursement conditions, patient selection and equipment costs will determine the extent of adoption outside conventional hospitals. Asia-Pacific – Fastest-Advancing Geography Asia-Pacific is projected to register the fastest regional CAGR of 7.4% during 2026–2032, increasing from an estimated USD 2.260 billion in 2025 to USD 3.735 billion by 2032. Japan's National Clinical Database recorded 6,219 laparoscopic partial hepatectomies in a specified procedural category during 2024, demonstrating established minimally invasive liver surgery activity in one of the region's major healthcare markets. Expansion of specialist surgical services in China and India could increase demand for advanced laparoscopic, robotic and liver resection equipment. Country-specific procurement prices, surgical access and the number of completed complex HPB procedures remain the major uncertainties in the regional forecast. Which Companies Are Shaping the Competitive Landscape of the HPB Surgical Devices Market? Johnson & Johnson MedTech: ETHICON Surgical Stapling Portfolio Strengthens Its Position in HPB Procedures Johnson & Johnson MedTech is a major competitor in the HPB Surgical Devices Market through its ETHICON surgical stapling, tissue sealing, and surgical closure portfolio. The U.S. FDA granted 510(k) clearance for the ETHICON 4000 Stapler and 3D Reloads on May 14, 2025, with indications including transection and resection of liver parenchyma, hepatic vasculature, biliary structures, and pancreatic tissue. The company subsequently received European CE Mark certification for the ETHICON 4000 on April 22, 2026, expanding its regulatory access across major surgical markets. These developments strengthen Johnson & Johnson's competitive position in instruments used during complex tissue resection and reconstruction, where recurring stapler reload consumption, surgeon preference, and hospital procurement agreements influence device purchasing. Source: U.S. FDA — K250835 | Johnson & Johnson, April 2026 Medtronic: Hugo Robotic Surgery Expansion and LigaSure Strengthen Its Surgical Device Portfolio Medtronic competes in the HPB Surgical Devices Market through its LigaSure vessel-sealing technology, surgical stapling systems, advanced energy instruments, and Hugo robotic-assisted surgery platform. On November 17, 2026, Medtronic announced U.S. FDA clearance for Hugo in general surgery, including cholecystectomy, within a broader group of indications representing approximately 3.5 million annual U.S. surgical procedures. The company also reported that LigaSure vessel-sealing technology had been used in more than 45 million open and laparoscopic procedures across surgical specialties. These figures demonstrate the scale of its established surgical technology portfolio, although they are not HPB-specific procedure counts. Medtronic's commercial opportunity includes expanding robotic adoption within eligible abdominal operations while using its established energy-device portfolio to compete for recurring surgical instrument purchasing. Source: Medtronic, November 2026 Olympus Corporation: VISERA ELITE III Expands Competition in HPB Surgical Visualization Olympus Corporation is an established supplier of surgical visualization and minimally invasive imaging technologies relevant to liver, pancreatic, biliary, and transplant operations. On March 11, 2026, Olympus launched VISERA ELITE III in the United States, incorporating 4K imaging, 3D visualization, and infrared fluorescence-guided imaging into a multispecialty surgical platform. In the company's supporting clinical survey, eight out of ten surgeons agreed that its Yellow Enhancement imaging feature may assist in identifying critical anatomical structures within adipose tissue. Olympus specifically identifies HPB and transplant surgery among the platform's supported specialties. The system's multispecialty compatibility and software-based upgrade capabilities provide Olympus with opportunities in hospital imaging replacement and modernization, where capital-equipment purchasing increasingly depends on utilization across several surgical departments. Source: Olympus, March 2026 Other Key Companies and Their Roles: Intuitive Surgical: Competes through the da Vinci robotic surgical platform and associated instruments used in eligible minimally invasive abdominal procedures. The company reported a global installed base of 12,094 da Vinci systems as of September 30, 2026, providing an established robotic infrastructure for specialist HPB programs. Integra LifeSciences: Supplies CUSA Clarity ultrasonic surgical aspirators and MicroFrance laparoscopic instruments relevant to liver resection and transplantation. In September 2026, the company highlighted 20 years of CUSA technology within its portfolio, emphasizing specialized liver surgery applications and surgeon education. Stryker Corporation: Develops advanced surgical imaging systems, including the L12 LED Light Source with AIM. The system received FDA clearance on February 12, 2026, with indications covering near-infrared visualization of major extrahepatic bile ducts in eligible patients. KARL STORZ: Supplies laparoscopic imaging, surgical access devices, hand instruments, and minimally invasive surgical equipment used across general and HPB procedures. Its competitive position is associated with integrated endoscopic visualization systems and established hospital instrumentation portfolios. Boston Scientific Corporation: Supplies WallFlex biliary stents, SpyGlass visualization systems, AXIOS drainage systems, and EXALT duodenoscopes. These products primarily serve the adjacent pancreatobiliary endoscopic intervention market, rather than the core operative HPB surgical devices market. Cook Medical: Provides biliary access, drainage, and endoscopic intervention devices for pancreaticobiliary conditions. Its portfolio is primarily relevant to the extended HPB surgical and interventional devices market and should be classified separately from operative surgical instruments. What Are the Key Trends Shaping the Global HPB Surgical Devices Market? Increasing Adoption of Robotic-Assisted HPB Surgery: Robotic surgical platforms are gaining adoption in liver resections, pancreaticoduodenectomy, distal pancreatectomy, and selected biliary operations. Manufacturers such as Intuitive Surgical and Medtronic are expanding robotic capabilities for abdominal surgery, intensifying competition in robotic instruments and accessories. Hospital purchasing decisions increasingly depend on surgical case volumes, surgeon training, platform utilization, and the cost of robotic procedures compared with conventional laparoscopy. Expansion of Minimally Invasive Liver and Pancreatic Surgery: Laparoscopic and robotic approaches are being adopted for a broader range of complex HPB operations at specialist centers. Hospitals are investing in surgical access instruments, advanced energy devices, and visualization systems to support minimally invasive procedures. This shift is changing device purchasing patterns, with greater emphasis on instruments compatible with laparoscopic and robotic workflows while maintaining the availability of conventional devices for complex open surgery. Growing Integration of Fluorescence-Guided Surgical Imaging: Surgical imaging manufacturers are integrating near-infrared fluorescence, 3D visualization, and high-definition imaging into operating-room platforms. Olympus and Stryker are advancing technologies relevant to identifying biliary anatomy and supporting complex hepatobiliary procedures. Integrated imaging capabilities are influencing equipment replacement decisions, particularly among hospitals seeking visualization systems that can be used across multiple surgical specialties. Increasing Use of Specialized Liver Resection and Tissue Dissection Devices: HPB centers are adopting specialized ultrasonic surgical aspirators, advanced energy instruments, and other tissue-dissection technologies for complex hepatic operations. Manufacturers such as Integra LifeSciences are targeting liver resection and transplantation applications with dedicated surgical instruments. Demand is concentrated in specialist hospitals, where device selection depends on surgical requirements, surgeon familiarity, and utilization across different liver procedures. Shift Toward Parenchymal-Sparing Liver Surgery and Surgical Ablation: Liver surgery is increasingly incorporating tissue-preserving resection techniques and selected operative ablation procedures. These approaches are changing demand for dissection instruments, intraoperative ultrasound, surgical imaging, and ablation equipment. Manufacturers serving liver surgery must account for shifts in procedural mix, as growth in less extensive operations can redistribute equipment spending away from conventional major resection technologies. Increasing Competition in Advanced Surgical Stapling and Vessel Sealing: Johnson & Johnson, Medtronic, and other manufacturers are developing advanced stapling, tissue closure, and vessel-sealing technologies for complex abdominal surgery. Hospitals are evaluating device reliability, instrument compatibility, consumable expenditure, and performance across different procedures. The increasing availability of alternative surgical technologies creates opportunities for supplier switching while placing greater pressure on product differentiation and purchasing contracts. Greater Emphasis on Cost-Effective Robotic and Laparoscopic Surgery: Hospitals are increasingly evaluating the total cost of surgical procedures, including disposable instruments, operating-room utilization, equipment maintenance, and staff training. Conventional laparoscopic surgery remains economically competitive in routine gallbladder operations, while robotic systems are being evaluated more selectively for complex procedures. Manufacturers must demonstrate clinical and operational value to justify premium instruments and additional capital-equipment investment. Expansion of Specialized HPB Surgical Centers and Training Programs: Complex liver, pancreatic, and biliary operations are increasingly concentrated in hospitals with dedicated HPB surgical teams and advanced operating-room capabilities. Manufacturers are strengthening clinical education, surgical training, and specialist-center partnerships to support device adoption. Purchasing opportunities depend on procedure throughput, surgeon experience, and the ability of hospitals to sustain utilization of specialized instruments and equipment. Increasing Focus on Surgical Device Safety and Regulatory Compliance: Regulatory scrutiny of surgical staplers, robotic instruments, and other operative devices is influencing product development, post-market surveillance, and hospital procurement. Device manufacturers face greater requirements for performance monitoring, product traceability, and corrective actions when safety issues arise. Hospitals may prioritize established safety records and dependable product supply when selecting instruments for complex HPB operations. Growing Role of Endoscopic and Image-Guided Alternatives in HPB Treatment: Therapeutic endoscopy, percutaneous interventions, and image-guided ablation are changing treatment pathways for selected pancreatic and biliary conditions. These alternatives can reduce the need for conventional operations in eligible patients, potentially shifting demand away from certain surgical instruments. Manufacturers operating across both surgical and interventional portfolios are better positioned to address changes in treatment selection, while companies focused exclusively on operative devices face procedure-substitution risks. What Will Shape Revenue Opportunities in the HPB Surgical Devices Market Through 2032? The commercial foundation of the HPB Surgical Devices Market remains concentrated in laparoscopic gallbladder surgery and complex liver and pancreatic operations. High cholecystectomy volumes sustain recurring demand for energy devices, surgical clips, staplers, and access instruments, while liver transplantation and pancreatic resection generate demand for specialized surgical equipment. Johnson & Johnson's ETHICON stapling portfolio, Medtronic's vessel-sealing technologies, and Integra LifeSciences' liver dissection systems compete across these applications, where completed procedure volumes and device utilization determine purchasing demand. The strongest emerging opportunities are associated with robotic-assisted HPB surgery, fluorescence-guided visualization, and specialized liver resection technologies. Medtronic's expansion of the Hugo robotic platform into general surgery and Olympus' introduction of VISERA ELITE III are increasing competition in advanced surgical equipment. Greater adoption of minimally invasive liver and pancreatic procedures could increase demand for robotic instruments, integrated imaging systems, and advanced tissue-dissection devices, particularly in specialist HPB centers with sufficient surgical volumes to support equipment investment. For manufacturers, the principal commercial constraints remain high robotic procedure costs, hospital capital budgets, surgical device safety, specialist surgeon availability, and competition from conventional laparoscopic and nonsurgical interventions. Procurement standardization and pressure to reduce disposable instrument expenditure may limit revenue growth per procedure, even as surgical activity expands. Market performance through 2032 will depend on the conversion of clinical demand into completed operations, adoption of cost-effective surgical technologies, and sustained instrument utilization across hospitals and specialized HPB surgical centers. Analyst Commentary: Where Can HPB Surgical Device Manufacturers Capture Growth Opportunities Through 2032? The HPB Surgical Devices Market presents significant opportunities in high-volume laparoscopic procedures, complex liver and pancreatic surgery, and advanced surgical technologies. Manufacturers supplying energy devices, surgical staplers, access instruments, and tissue-dissection systems can benefit from recurring procedural demand, while specialized HPB centers offer opportunities for higher-value instruments used in hepatic resection, pancreatic reconstruction, and transplantation. Robotic-assisted surgery and integrated surgical visualization represent important areas of competitive expansion, with Medtronic, Intuitive Surgical, Olympus, and Johnson & Johnson strengthening their surgical technology portfolios. However, higher equipment costs, hospital procurement pressure, and competition from conventional laparoscopic procedures may limit adoption in cost-sensitive surgical settings. Manufacturers that combine clinically differentiated technologies with competitive procedure-level costs, reliable instrument performance, and strong specialist-center relationships will be better positioned to capture incremental HPB surgical device revenue through 2032. HPB Surgical Devices Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 5.83 Billion Revenue Forecast in 2032 USD 8.98 Billion Overall Growth Rate CAGR of 6.4% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Product Type, By Surgical Approach, By Surgical Procedure / Application, By Indication, By End User, By Geography By Product Type Energy and Vessel Sealing Devices, Robotic-Assisted Surgical Systems and Instruments, Surgical Visualization and Imaging Systems, Surgical Hand and Access Instruments, Tissue Dissection and Resection Devices, Surgical Stapling and Closure Devices, Surgical Fluid Management and Drainage Devices, Hemostasis and Surgical Sealant Products, Other HPB Surgical Devices By Surgical Approach Laparoscopic Surgery, Robotic-Assisted Surgery, Open Surgery By Surgical Procedure / Application Gallbladder Surgery, Liver Resection and Surgical Ablation, Pancreatic Surgery, Liver Transplantation, Biliary Tract Surgery, Other HPB Surgical Procedures By Indication Gallstones and Cholecystitis, Liver Cancer, Pancreatic Cancer, Bile Duct and Gallbladder Cancer, Liver Cirrhosis and End-Stage Liver Disease, Benign Pancreatic Diseases, Other HPB Conditions By End User Hospitals, Ambulatory Surgical Centers, Other Surgical Facilities By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Adoption of minimally invasive HPB surgery, liver transplantation activity, recurring instrument use in gallbladder procedures, specialized device requirements in pancreatic and liver surgery, advances in robotic surgery and intraoperative visualization Customization Option Available upon request Frequently Asked Question About This Report Q1. How is the growing preference for minimally invasive procedures influencing demand in the HPB surgical devices market? A1. Increasing use of laparoscopic and robotic procedures is supporting demand for specialized surgical instruments. Laparoscopic surgery accounted for an estimated 64% revenue share in 2025. Hospitals are investing in advanced energy devices and visualization systems to support liver resections, pancreatic operations, and gallbladder surgery. Q2. What are the latest technological innovations transforming the industry? A2. Robotic surgical platforms and fluorescence-guided imaging are expanding advanced surgical capabilities. Medtronic received FDA clearance for its Hugo robotic platform in general surgery in November 2026. Olympus also introduced VISERA ELITE III with 4K imaging and fluorescence visualization in March 2026, creating additional options for specialist HPB surgical centers. Q3. Which surgical applications offer the strongest commercial opportunities in the market? A3. Gallbladder surgery remains the largest application with an estimated 51.4% revenue share in 2025. High procedure volumes support recurring demand for surgical clips and laparoscopic instruments. Biliary tract surgery is projected to grow at a CAGR of 9.2% through 2032, creating opportunities for specialized reconstruction and dissection devices. Q4. How are companies expanding their product portfolios to strengthen competition in the industry? A4. Manufacturers are developing advanced surgical staplers and integrated robotic systems to serve complex HPB procedures. Johnson & Johnson received FDA clearance for its ETHICON 4000 Stapler in May 2025, while Medtronic is expanding its Hugo robotic platform. These developments increase competition for hospital equipment purchases and recurring surgical consumables. Q5. Which regions are expected to generate the highest growth in the HPB surgical devices market? A5. Asia-Pacific leads with an estimated 38.7% revenue share in 2025 and is projected to grow fastest at a CAGR of 7.4% through 2032. Japan recorded 120,625 laparoscopic cholecystectomies in 2024. Expanding specialist surgical capabilities in China and India could further support demand for advanced HPB instruments. Q6. What factors are making robotic surgery more attractive to the industry? A6. Robotic systems are gaining attention for complex liver and pancreatic procedures requiring specialized surgical capabilities. A 2026 registry study involving 8,928 minimally invasive liver resections found that robotic utilization increased from 10.4% to 42.2% between 2015 and 2025. This shift creates opportunities for robotic instruments and compatible surgical equipment. Q7. What are the major challenges affecting expansion of the HPB surgical devices market? A7. High robotic equipment costs and hospital procurement constraints can slow adoption. A 2025 U.S. study reported average disposable instrument costs of USD 1,447 for robotic cholecystectomy compared with USD 669 for laparoscopic procedures. Surgeon training requirements and competition from lower-cost surgical alternatives also influence purchasing decisions. Sources: U.S. Health Resources and Services Administration – The United States Performed 12,344 Liver Transplants in 2025, According to Official Data Reviewed in August 2026 HRSA – Organ Transplantation Statistics: Liver Transplant Volumes and Waiting Lists U.S. FDA – ETHICON 4000 Staplers Received Expanded Clearance on May 14, 2025, Covering Transection and Resection of Liver Parenchyma, Hepatic Vasculature, Biliary Structures, and Pancreas FDA – ETHICON 4000 Staplers and 3D Reloads: K250835 Clearance and Expanded Surgical Indications Johnson & Johnson – Announced European CE Mark Approval for the ETHICON 4000 Stapler on April 22, 2026, Expanding Availability of Its Advanced Stapling Technology for Open and Laparoscopic Surgery Johnson & Johnson – CE Mark Approval for the ETHICON 4000 Stapler Olympus – Launched VISERA ELITE III in the United States on March 11, 2026, Combining 4K, 3D, and Fluorescence-Guided Imaging for Surgical Specialties Including HPB and Transplant Surgery Olympus – U.S. Launch of the VISERA ELITE III Surgical Imaging Platform Integra LifeSciences – Announced Liver Surgery Education Featuring CUSA Clarity and MicroFrance Laparoscopic Instruments on September 25, 2026; CUSA Clarity’s Indications Include Liver Resection and Transplant Surgery Integra LifeSciences – CUSA Technology and Liver Surgery Education at ACS Clinical Congress 2026 Medtronic – Submitted U.S. Regulatory Filings for Hugo Robotic-Assisted General Surgery and the LigaSure RAS Maryland Instrument on June 3, 2026, Supporting Its Broader Abdominal Surgical Technology Expansion Medtronic – Hugo General Surgery and LigaSure RAS Regulatory Submissions U.S. FDA – Cleared an Updated Packaging Configuration for Stryker’s L12 LED Light Source With AIM on February 12, 2026, Retaining Existing Near-Infrared Visualization Indications for Major Extrahepatic Bile Ducts FDA – Stryker L12 LED Light Source With AIM: K260108 Clearance and Biliary Imaging Indications Table of Contents – Global HPB Surgical Devices Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product Type, Surgical Approach, Surgical Procedure / Application, Indication, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product Type, Surgical Approach, Surgical Procedure / Application, Indication, End User, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Surgical Approach, Surgical Procedure / Application, Indication, and End User Investment Opportunities in the HPB Surgical Devices Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Robotic-Assisted Surgical Systems, Energy and Vessel Sealing Devices, Surgical Visualization and Imaging Systems, Tissue Dissection and Resection Devices, Surgical Stapling and Closure Devices, and Specialized Liver Resection Technologies Investment Opportunities in Minimally Invasive HPB Surgery, Fluorescence-Guided Imaging, and Advanced Surgical Technologies through 2032 Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of HPB Surgical Devices in Liver Resection, Pancreatic Surgery, Gallbladder Surgery, Biliary Reconstruction, and Liver Transplantation Role of Laparoscopic and Robotic-Assisted Surgical Technologies in HPB Procedures Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Procedure-Volume Assessment and Device Expenditure Estimation Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Healthcare Procurement Factors Role of Rising HPB Surgical Volumes, Liver Transplantation Activity, and Minimally Invasive Procedures in Market Expansion Impact of Robotic-Assisted Surgery, Advanced Energy Devices, Surgical Visualization, and Specialized Tissue-Dissection Technologies Influence of Hospital Capital Costs, Disposable Instrument Expenditure, Surgeon Training, and Surgical Capacity Impact of Endoscopic and Image-Guided Alternatives on Operative HPB Device Demand Global HPB Surgical Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type: Energy and Vessel Sealing Devices Robotic-Assisted Surgical Systems and Instruments Surgical Visualization and Imaging Systems Surgical Hand and Access Instruments Tissue Dissection and Resection Devices Surgical Stapling and Closure Devices Surgical Fluid Management and Drainage Devices Hemostasis and Surgical Sealant Products Other HPB Surgical Devices Market Analysis by Surgical Approach: Laparoscopic Surgery Robotic-Assisted Surgery Open Surgery Market Analysis by Surgical Procedure / Application: Gallbladder Surgery Liver Resection and Surgical Ablation Pancreatic Surgery Liver Transplantation Biliary Tract Surgery Other HPB Surgical Procedures Market Analysis by Indication: Gallstones and Cholecystitis Liver Cancer Pancreatic Cancer Bile Duct and Gallbladder Cancer Liver Cirrhosis and End-Stage Liver Disease Benign Pancreatic Diseases Other HPB Conditions Market Analysis by End User: Hospitals Ambulatory Surgical Centers Other Surgical Facilities Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America HPB Surgical Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Surgical Approach, Surgical Procedure / Application, Indication, and End User Country-Level Breakdown: United States Canada Europe HPB Surgical Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Surgical Approach, Surgical Procedure / Application, Indication, and End User Country-Level Breakdown: Germany France United Kingdom Italy Spain Rest of Europe Asia Pacific HPB Surgical Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Surgical Approach, Surgical Procedure / Application, Indication, and End User Country-Level Breakdown: China Japan India South Korea Australia Rest of Asia-Pacific Latin America HPB Surgical Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Surgical Approach, Surgical Procedure / Application, Indication, and End User Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa HPB Surgical Devices Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Surgical Approach, Surgical Procedure / Application, Indication, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Johnson & Johnson MedTech Medtronic plc Olympus Corporation Intuitive Surgical, Inc. Integra LifeSciences Holdings Corporation Stryker Corporation KARL STORZ SE & Co. KG Boston Scientific Corporation Cook Medical B. Braun SE CONMED Corporation Applied Medical Resources Corporation Zimmer Biomet Holdings, Inc. Smith+Nephew plc Competitive Landscape and Strategic Insights Benchmarking Based on Surgical Instrument Portfolios, Robotic Capabilities, Visualization Technologies, Product Performance, and Regional Presence Supplier Qualification and Regulatory Compliance Capability Analysis Robotic-Assisted Surgical Systems and Instrument Portfolio Positioning Energy and Vessel Sealing Technology Competitiveness Surgical Visualization, Fluorescence Imaging, and Intraoperative Imaging Strategy Analysis Liver Resection, Tissue Dissection, Stapling, and Closure Device Portfolio Analysis Competitive Positioning in Laparoscopic and Open HPB Surgical Equipment Appendix Abbreviations and Terminologies Used in the Report References and Sources Historical Procedure-Volume References (2019–2024) Base Year Data Sources and Assumptions (2025) Forecast Assumptions and Market Outlook (2026–2032) List of Tables Market Segmentation by Product Type, Surgical Approach, Surgical Procedure / Application, Indication, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Country-Level HPB Surgical Devices Market Breakdown Competitive Benchmarking of Leading HPB Surgical Device Vendors Robotic-Assisted, Laparoscopic, and Open Surgical Technology Comparison Surgical Instrument Portfolio and Product Application Analysis Procedure-Volume Assessment Across Gallbladder, Liver, Pancreatic, Biliary, and Transplant Surgery Regulatory Clearance, Surgical Device Safety, and Procurement Analysis Technology Adoption Trends Across Energy Devices, Visualization Systems, Tissue Dissection, Stapling, and Closure Products List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Surgical Approach, Surgical Procedure / Application, Indication, and End User (2025 vs. 2032) Global HPB Surgical Devices Ecosystem and Value Chain Analysis